Puerto Vallarta, Mexico – The World Health Organization (WHO) has designated JN.1 as a “variant of concern” while emphasizing that the global public health risk remains low, based on available evidence. However, with the onset of winter in the northern hemisphere, experts fear that JN.1 could potentially exacerbate respiratory infections in affected nations.
In a departure from the typical Covid-19 symptoms such as a runny nose, cough, headaches, and weakness, individuals infected with the JN.1 variant have reported additional issues, including problems sleeping and heightened anxiety. Surprisingly, fewer cases of loss of taste and smell have been documented in connection with this variant.
Dr. Thomas Russo, a professor and chief of infectious diseases at the University at Buffalo in New York, raised concerns about the potential for increased transmissibility with JN.1. He stated, “Some data suggests that the BA.2.86 subvariant of JN.1 could be more transmissible than its predecessors. Given that JN.1 is a descendant of BA.2.86, there is growing concern regarding its transmissibility. Fortunately, the updated vaccines are more closely aligned with JN.1, offering hope that they will continue to provide protection against severe disease.”
In the United States, the JN.1 variant now accounts for approximately 20% of new Covid-19 cases, making it the fastest-growing variant, according to the CDC. JN.1 is believed to have evolved from BA.2.86, also known as Pirola, which garnered international attention earlier in the year due to its significant spike protein mutations, totaling more than 30.
The CDC has reported that the prevalence of JN.1 in the United States more than doubled between late November and mid-December, underscoring the urgency of monitoring and addressing this emerging variant.
While health authorities continue to closely monitor the situation, ongoing research and the development of vaccines tailored to JN.1 remain pivotal in the fight against this evolving threat. Public health measures and vaccination campaigns are crucial to mitigate the impact of this new variant and protect vulnerable populations.
Puerto Vallarta, Mexico - The World Health Organization (WHO) has designated JN.1 as a "variant of concern" while emphasizing that the global public health . . .
